EUVIMEDEUVIMED entdecken
Kohortenstudie

L26/P-165 Beyond the biopsy-Cumulative live birth rates following Non-invasive chromosome screening (NICS) versus Trophectoderm biopsy in advanced maternal age: A prospective cohort study

V. Kumar, S. Dongre, D. Kumar

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.501 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von V. Kumar und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does non-invasive chromosome screening (NICS) of spent culture medium yield comparable cumulative live birth rates (CLBR) to invasive trophoectoderm biopsy (TE-PGT) in advanced maternal age? Summary answer NICS provides equivalent cumulative live birth rates and clinical outcomes compared to TE-PGT for women aged 35–45, offering a non-invasive, safe and effective alternative. What is known already Embryo aneuploidy is the leading cause of IVF failure in advanced maternal age. While TE-PGT is the current clinical standard for screening, concerns persist regarding its invasive nature, potential embryo damage, and technical complexity. Non-invasive chromosome screening (NICS) utilizes cell-free DNA from spent culture medium, offering a safer diagnosis; however, robust prospective data comparing its efficacy to invasive biopsy regarding the “gold standard” of cumulative live birth rates (CLBR) has been limited until now. Study design, size, duration This is a prospective cohort study and was conducted over three years (2022–2025). A total of 349 patients aged 35–45 undergoing ICSI were recruited. The study size included 143 patients in the NICS group and 206 in the TE-PGT group. All participants underwent frozen single embryo transfer (SET), and the primary endpoint was the cumulative live birth rate per retrieval cycle. Participants/materials, setting, methods Women aged 35–45 undergoing ICSI at a single fertility center were enrolled. Chromosomal analysis was performed via Next-Generation Sequencing (NGS). In the NICS group, DNA was sequenced from spent culture medium; in the TE-PGT group, DNA was obtained from biopsied trophectoderm cells. Morphological selection was used as a baseline control. Key variables like BMI, AMH, and oocyte yield were monitored to ensure group comparability. Main results and the role of chance Baseline demographics, including age and ovarian reserve, were comparable between groups. The primary analysis revealed no significant difference in the CLBR between the NICS group and the TE-PGT group (p > 0.05). Secondary outcomes, including biochemical pregnancy rates and cumulative pregnancy loss rates, also demonstrated equivalent performance between the two screening methods. Importantly, after adjusting for confounding factors, both NICS and TE-PGT significantly improved clinical outcomes compared to morphological selection alone. The role of chance was minimized through the prospective design and rigorous NGS protocols. While NICS utilizes cell-free DNA, which can be subject to maternal contamination, the comparable CLBR suggests that these technical differences do not diminish the overall clinical success when compared to invasive biopsy. This study confirms that for patients in the 35–45 age bracket, the non-invasive approach is a viable alternative for the invasive standard of care. Limitations, reasons for caution 1.NICS historically faces a lower informative rate due to variable cell-free DNA quantities. 2.Findings are limited by the single-center setting. 3.Caution is advised regarding differing mosaicism thresholds (30% for TE-PGT vs. 40% for NICS), which may influence embryo selection and require standardized interpretation protocols across laboratories. Wider implications of the findings These findings suggest NICS can streamline genetic screening by removing technical and safety barriers associated with biopsies. It offers a patient-centered, non-invasive alternative that maintains high cumulative success rates, potentially shifting the standard of care for advanced maternal age patients globally. Trial registration number No

Zitieren

APA

Kumar, V., Dongre, S., & Kumar, D. (2026). L26/P-165 Beyond the biopsy-Cumulative live birth rates following Non-invasive chromosome screening (NICS) versus Trophectoderm biopsy in advanced maternal age: A prospective cohort study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.501

Vancouver

Kumar V, Dongre S, Kumar D. L26/P-165 Beyond the biopsy-Cumulative live birth rates following Non-invasive chromosome screening (NICS) versus Trophectoderm biopsy in advanced maternal age: A prospective cohort study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.501

BibTeX
@article{Kumar2026,
  author = {Kumar, V. and Dongre, S. and Kumar, D.},
  title = {L26/P-165 Beyond the biopsy-Cumulative live birth rates following Non-invasive chromosome screening (NICS) versus Trophectoderm biopsy in advanced maternal age: A prospective cohort study},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.501}
}
Kostenlos starten →